Process for manufacturing chewable dosage forms for drug delivery and products thereof
US-9381155-B2 · Jul 5, 2016 · US
US12083218B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12083218-B2 |
| Application number | US-202117447453-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 13, 2021 |
| Priority date | Oct 18, 2018 |
| Publication date | Sep 10, 2024 |
| Grant date | Sep 10, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the soft chewable dosage form and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the soft chewable dosage form.
Opening claim text (preview).
The invention claimed is: 1. A method for treating a subject suffering from a disease or disorder in the gastro intestinal tract comprising administering a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material/matrix comprising a first lipid and a second lipid, wherein the second lipid is a plasticizer, wherein the lipid encapsulated active pharmaceutical ingredient is embedded in the soft chewable dosage form, and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient. 2. A method according to claim 1 , wherein the disease or disorder in the gastro intestinal tract is peptic ulcers, gastric ulcers, hyperacidity, gastroesophageal reflux disease (GERD), or gastritis. 3. A method according to claim 1 , wherein the disease or disorder in the gastro intestinal tract leads to heartburn, gas, indigestion, upper abdominal fullness, heartburn, nausea, belching, upper abdominal pain, or feeling full earlier than expected when eating.
1,3-Thiazoles · CPC title
Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant · CPC title
Flavour masking or reducing agents · CPC title
containing sugars or derivatives · CPC title
using additives (addition of substantially indigestible substances A23L33/21) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.